O

Orlando Clinical Research Center | Orlando, FL

Research site
(Unclaimed)
Location
5055 South Orange Avenue, Orlando, Florida, United States of America
Site insights

Top conditions

Liver Diseases (59 trials)

Renal Insufficiency (53 trials)

Hepatitis C (22 trials)

Hepatitis (17 trials)

Chronic Hepatitis C (15 trials)

Top treatments

BMS-986177
Daclatasvir
BMS-650032
BMS-790052
Telmisartan
Lorcaserin
Fruquintinib
SR141716
Tirzepatide
Voxilaprevir

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

13 of 211
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.

The purpose of this study is to evaluate the effect of hepatic impairment on the systemic pharmacokinetics (PK), safety, and tolerability of JDQ443 i...

Enrolling
Small Cell Lung Carcinoma
Drug: JDQ443

The study investigates an investigational drug called etavopivat in participants with hepatic impairments and participants with normal hepatic functi...

Not yet enrolling
Liver Diseases
Drug: Etavopivat

The purpose of this study is to characterize the single-dose pharmacokinetic (PK) of apalutamide in participants with severe hepatic impairment relat...

Enrolling
Hepatic Impairment
Drug: Apalutamide

The main purpose of this study is to assess the amount of study drug (LY3473329) that reaches the bloodstream and the time it takes for the body to g...

Enrolling
Renal Insufficiency
Drug: LY3473329

The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream and how long it takes the body to eliminate it in partic...

Enrolling
Healthy
Hepatic Insufficiency
Drug: LY3502970

The main purpose of this study is to assess the amount of study drug (LY3502970) that reaches the bloodstream and the time it takes for the body to g...

Enrolling
Healthy
Renal Insufficiency
Drug: LY3502970

The main aim of this study is to find out how the body processes 1 dose of TAK-279 (pharmacokinetics) in participants with kidney problems compared t...

Enrolling
Healthy Volunteers
Renal Impairment
Drug: TAK-279

The main aim of this study is to find out how the body processes 1 dose of TAK-279 (pharmacokinetics) in participants with liver problems compared to...

Enrolling
Hepatic Impairment
Healthy Volunteers
Drug: TAK-279

The rationale of this study is to evaluate the impact of renal function on the PK, safety, and tolerability of VIR-2218 in participants with normal r...

Enrolling
Renal Impairment
Drug: VIR-2218

The purpose of this study is to understand how the loss of kidney function affects study medicine (PF-07923568) in the body. People with some level o...

Enrolling
Renal Impairment
Drug: Drug: PF-07923568

This study is open to people with and without severe liver problems. People can join the study if they are 18 to 80 years of age and have a body mass...

Enrolling
Healthy
Liver Diseases
Drug: Avenciguat (BI 685509)

This study will investigate the pharmacokinetics, safety, and tolerability of DZD9008 in subjects with hepatic impairment compared to subjects with n...

Enrolling
Hepatic Impairment
Drug: DZD9008

The goals of this study are to measure the amount of bulevirtide (BLV) that gets into the blood stream and how long it takes to get rid of it, measur...

Enrolling
Chronic Hepatitis D Infection
Drug: Bulevirtide

Trial sponsors

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS) (22 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems